With their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Amanda Przespolewski, DO
Advertisement
Articles by Amanda Przespolewski, DO
Key advances in ALL treatment from ASCO 2023 are discussed by Dr Przespolewski.
Dr Aldoss discusses the role ponatinib and blinatumomab in the management of Ph+ALL.
Medical experts highlight recent findings from the PhALLCON study.
Drs Aldoss and Przespolewski evaluate the changing treatment landscape for patients diagnosed with Ph+ ALL.
Amanda Przespolewski, DO, and Ibrahim Aldoss, MD define and discuss how to diagnose patients with Ph+ALL.
Advertisement
Latest Updated Articles
Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALLPublished: July 12th 2023 | Updated:
- Ponatinib and Blinatumomab Use in Patients with Newly Diagnosed Ph+ ALL
Published: July 5th 2023 | Updated:
- Recent Updates from the PhALLCON Study
Published: July 5th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5